Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Chronic Pain Indications Will Be Harder To Come By, FDA Says

Executive Summary

A general chronic pain indication may elude Eli Lilly's Cymbalta near the finish line because FDA has changed its thinking about the evidence needed to support the claim

You may also be interested in...

Cymbalta Adds Musculoskeletal Pain Claim Despite Advisory Committee Concerns

Label for duloxetine's new use emphasizes that efficacy was shown only in patients with chronic lower back pain and osteoarthritis.

Cymbalta Chronic Pain Label: FDA Expresses Faith In Physicians' Judgment

FDA may place more faith in physician diligence to read updated labeling as it manages the risk for Eli Lilly's Cymbalta in some chronic pain indications

Cymbalta Could Get "Fairly Narrow Broad Indication" For Pain, FDA's Rappaport Says

Agency favors a claim for musculoskeletal pain, but advisory committee members suggest considering the cause, not just the location of the pain, in the indication.

Related Content


Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts